Drug Information

Drug General Information
Drug ID
D05VEV
Former ID
DNC006566
Drug Name
Ac-hPhe-Leu-Ala-LeuVSMe
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528196]
Formula
C29H46N4O6S
Canonical SMILES
CC(C)CC(C=CS(=O)(=O)C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(<br />CCC1=CC=CC=C1)NC(=O)C
InChI
1S/C29H46N4O6S/c1-19(2)17-24(15-16-40(7,38)39)32-27(35)21(5)30-29(37)26(18-20(3)4)33-28(36)25(31-22(6)34)14-13-23-11-9-8-10-12-23/h8-12,15-16,19-21,24-26H,13-14,17-18H2,1-7H3,(H,30,37)(H,31,34)(H,32,35)(H,33,36)/b16-15+/t21-,24+,25-,26-/m0/s1
InChIKey
WUQZWLVEKPBGGU-WXIXLNPNSA-N
PubChem Compound ID
11556056
Target and Pathway
Target(s) Cathepsin B Target Info Inhibitor [528196]
Cathepsin S Target Info Inhibitor [528196]
KEGG Pathway Lysosome
Antigen processing and presentationhsa04142:Lysosome
Phagosome
Antigen processing and presentation
Tuberculosis
NetPath Pathway TCR Signaling Pathway
IL2 Signaling PathwayNetPath_22:Leptin Signaling Pathway
IL2 Signaling Pathway
Reactome Collagen degradation
Trafficking and processing of endosomal TLR
Assembly of collagen fibrils and other multimeric structures
MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway
Degradation of the extracellular matrix
MHC class II antigen presentation
WikiPathways Class I MHC mediated antigen processing & presentation
Trafficking and processing of endosomal TLR
References
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.